General Information

We are a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases. We believe that our monoclonal antibodies, or mAbs, offer a novel approach to address serious infections. Unlike antibiotics that propagate resistance, disrupt both disease-causing and beneficial bacteria and have adverse off-target effects, mAbs have the ability to precisely bind only to the intended target, thereby avoiding these undesired consequences. Our lead product candidate, ASN100, is a first-in-class mAb therapeutic in Phase 2 clinical development for the prevention of Staphylococcus aureus, or S. aureus, pneumonia in high-risk, mechanically ventilated patients, a potentially life-threatening and costly infection for which there are no approved preventive therapies. In addition to ASN100, our preclinical pipeline is comprised of mAbs targeting multiple serious bacterial and viral pathogens, including respiratory syncytial virus, or RSV.


Employees: 39
Founded: 2010
Contact Information
Address 890 Winter Street, Suite 230, Waltham, MA 02451, US
Phone Number (781) 819-5704
Web Address
View Prospectus: Arsanis
Financial Information
Market Cap $136.9mil
Revenues $0 mil (last 12 months)
Net Income $-28.1 mil (last 12 months)
IPO Profile
Symbol ASNS
Exchange NASDAQ
Shares (millions): 4.0
Price range $10.00 - $10.00
Est. $ Volume $40.0 mil
Manager / Joint Managers Citigroup/ Cowen/ Piper Jaffray
CO-Managers -
Expected To Trade: 11/16/2017
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change